Another pointed to Merck not disclosing a termination of negotiations, which German law would have allegedly required if talks had ended, and reaffirmed their belief in SpringWorks' leadership.

How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.

– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will ...

Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...

In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark “Merck” internationally.

By Sriparna Roy (Reuters) - Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The ...

Merck said the bid represented a premium of 26% to SpringWorks’ unaffected 20-day average price of $37.38 on February 7, before Reuters disclosed potential for a transaction.

Shares in SpringWorks jumped Monday after Reuters reported that the company was in talks with Merck, closing 34% higher. This gave the Stamford, Conn.-based company a market value of $4.02 billion ...

Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and cancer, is in “advanced talks” to be acquired by Germany’s Merck ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and SpringWorks Therapeutics, Inc., a Stamford, Connecticut- based commercial-stage biopharmaceutical company focused on ...